Table 3 Results from sub group analysis on treatment success

Start year of study

 2000 or later [6, 11, 14, 30, 33–35, 38–42]

12

0.64

0.54

0.74

 1999 or earlier [31, 32, 36, 37]

4

0.60

0.44

0.77

Quality of study

 Very Low [6, 11, 14, 30–35, 39, 41]

11

0.65

0.54

0.75

 Low [36–38, 40, 42]

5

0.59

0.44

0.74

Adverse Events

  < 50 % [34–36]

3

0.76

0.70

0.82

  > 50 % [6, 31–33, 38, 40–42]

8

0.63

0.52

0.73

Type of treated patients

 New cases and previously treated [6, 30–32, 34–37, 39, 41, 42]

11

0.61

0.52

0.71

 Previously treated patients [11, 33, 38, 40]

4

0.66

0.53

0.78

HIV co-infected patients^a

 Yes [6, 11, 30, 32, 35, 37–40, 42]

10

0.57

0.49

0.64

 No [14, 30, 33–35]

6

0.72

0.65

0.79

Patient type

 MDR [6, 11, 14, 31, 33–36, 39–42]

12

0.67

0.56

0.78

 MDR and XDR [30, 32, 37]

3

0.51

0.48

0.55

 XDR [38]

1

0.48

0.30

0.66

DOTS-plus Provider

 Healthcare workers [30–32, 36, 38, 40–42]

8

0.59

0.48

0.69

 Home care support teams & Family [6, 11]

2

0.78

0.60

0.95

 Home care support teams [14]

1

0.71

0.62

0.80

 Healthcare workers & Family [33, 35]

2

0.72

0.61

0.83

 Family [34]

1

0.79

0.72

0.86

Drug Regimen Model

 Standardized [6, 11, 30, 33–36, 39, 42]

9

0.66

0.53

0.79

 Individualized [31, 32, 37, 38, 40, 41]

6

0.57

0.51

0.62

DOTS-plus Location

 Health center [14, 30, 33, 34]

4

0.70

0.56

0.84

 Patient home [6]

1

0.84

0.76

0.92

 Patient home and Health center [11, 31, 32, 35]

4

0.61

0.53

0.68

 Hospital [36–42]

7

0.57

0.44

0.69

Duration of DOTS-plus^a

 Throughout therapy [6, 11, 14, 30, 33–36, 40]

9

0.72

0.65

0.79

 Partial observation [31, 32, 38, 39, 42]

5

0.50

0.43

0.57

Length of treatment (months)^a

  < 18 [32, 42]

2

0.48

0.42

0.55

 18 & above [6, 11, 14, 30–35, 37, 39–41]

12

0.65

0.56

0.74

Drugs in regimen^a

 5 [11, 30–32, 34, 35, 37–39, 41, 42]

11

0.57

0.49

0.64

  > 5 [6, 33]

2

0.82

0.76

0.89